GSK Invests $100 Million in Vaccine Manufacturing

Article

Expansion at GSK’s Hamilton, MT site is designed to boost vaccine production capacity.

GlaxoSmithKline (GSK) announced plans to expand production capacity of key components of the adjuvant system used in several of the company’s vaccines, with an investment of $100 million in its manufacturing site in Hamilton, MT.

“For more than a decade, our Hamilton facility has supported GSK’s adjuvant system development program,” said Jack Bailey, president, US Pharmaceuticals, GSK in an April 24, 2019 press statement announcing the investment. “By expanding the adjuvant system production capabilities in Hamilton, we will continue to deliver long-term and sustainable supply for key vaccines, including SHINGRIX.”

The company reports that the site expansion is expected to add temporary construction and contracting jobs, as well as new permanent positions, including scientists, engineers, and manufacturing and quality professionals.

Hamilton is one of nine GSK manufacturing sites in the United States, and 86 sites globally.

Source: GSK

 

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.